Kana Takase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kana Takase has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Arisa Umesaki
Department of Neuroendovascular Surgery, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan
1 shared publication - Osamu Masuo
Department of Neuroendovascular Surgery, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan
1 shared publication - Shigeta Miyake
Department of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan
1 shared publication - Sujong Pak
Department of Neurosurgery, Yokosuka General Medical Center, Yokosuka, Japan
1 shared publication - Taisuke Akimoto
Department of Neurosurgery, Yokohama City University School of Medicine Graduate School of Medicine, Yokohama, Kanagawa, Japan
1 shared publication - Tetsuya Yamamoto
Department of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (3) , 433-440
The Utility of Antiplatelet Assay-Guided Individualized Dual Antiplatelet Therapy in Carotid Artery Stenting for Unstable Plaques
Objective : To evaluate the efficacy of individualized dual antiplatelet therapy (DAPT) using VerifyNow in reducing periprocedural ischemic complications following carotid artery stenting (CAS), particularly in patients with unstable plaques.Methods : This retrospective, single-center study included 187 patients who underwent elective CAS between January 2018 and September 2024. Patients were divided into two groups : a conventional DAPT (c-DAPT) group treated with aspirin and clopidogrel (n=89), and an individualized DAPT (i-DAPT) group (n=98) where antiplatelet regimens were adjusted based on preoperative platelet reactivity measured by VerifyNow. The primary outcome was the incidence of ischemic lesions on diffusion-weighted imaging (DWI) following CAS. Risk factors and the impact of DAPT personalization on ischemic changes were analyzed using multivariate logistic regression.Results : DWI-positive ischemic lesions were observed in 62.9% of the c-DAPT group and 51% of the i-DAPT group (p=0.07). Although the difference was not statistically significant, there was a trend toward reduced ischemic changes with individualized therapy. Multivariate analysis identified hypertension, diabetes mellitus, and unstable plaque as independent predictors of post-CAS ischemic changes. Subgroup analysis showed that VerifyNow-guided i-DAPT significantly reduced ischemic events in patients with unstable plaques (odds ratio, 0.49; p=0.03), whereas no significant effect was observed in other subgroups.Conclusion : VerifyNow-guided personalization of antiplatelet therapy is a safe and may have the potential to reduce periprocedural ischemic complications in CAS, particularly in patients with unstable plaques. Further multicenter prospective studies are needed to validate these findings and optimize individualized antiplatelet regimens.
- 1 May 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (3) , 433-440
Open AccessThe Utility of Antiplatelet Assay-Guided Individualized Dual Antiplatelet Therapy in Carotid Artery Stenting for Unstable Plaques
Objective : To evaluate the efficacy of individualized dual antiplatelet therapy (DAPT) using VerifyNow in reducing periprocedural ischemic complications following carotid artery stenting (CAS), particularly in patients with unstable plaques.Methods : This retrospective, single-center study included 187 patients who underwent elective CAS between January 2018 and September 2024. Patients were divided into two groups : a conventional DAPT (c-DAPT) group treated with aspirin and clopidogrel (n=89), and an individualized DAPT (i-DAPT) group (n=98) where antiplatelet regimens were adjusted based on preoperative platelet reactivity measured by VerifyNow. The primary outcome was the incidence of ischemic lesions on diffusion-weighted imaging (DWI) following CAS. Risk factors and the impact of DAPT personalization on ischemic changes were analyzed using multivariate logistic regression.Results : DWI-positive ischemic lesions were observed in 62.9% of the c-DAPT group and 51% of the i-DAPT group (p=0.07). Although the difference was not statistically significant, there was a trend toward reduced ischemic changes with individualized therapy. Multivariate analysis identified hypertension, diabetes mellitus, and unstable plaque as independent predictors of post-CAS ischemic changes. Subgroup analysis showed that VerifyNow-guided i-DAPT significantly reduced ischemic events in patients with unstable plaques (odds ratio, 0.49; p=0.03), whereas no significant effect was observed in other subgroups.Conclusion : VerifyNow-guided personalization of antiplatelet therapy is a safe and may have the potential to reduce periprocedural ischemic complications in CAS, particularly in patients with unstable plaques. Further multicenter prospective studies are needed to validate these findings and optimize individualized antiplatelet regimens.